Gary Gilliland, M.D., Ph.D.
President and Director
Fred Hutchinson Cancer Research Center
As president and director of Fred Hutch, Dr. Gilliland sets the strategic direction of the center, oversees center-wide initiatives and represents the Hutch’s interests to major partners and governmental bodies. Prior to taking the helm of Fred Hutch in January 2015, he held numerous clinical, research and leadership titles, including professor at Harvard Medical School and director of the leukemia program at the Dana-Farber/Harvard Cancer Center. He was senior vice president and global oncology franchise head at Merck and Co., where he successfully led the breakthrough immunotherapy drug Keytruda to market. And as vice dean of the Perelman School of Medicine, he spearheaded a new model for personalized medicine within the University of Pennsylvania system.
Dr. Gilliland’s background is as a researcher and clinician specializing in blood cancers like leukemia and myelodysplastic syndrome. He has made major contributions to the understanding of the genetic basis of blood diseases, particularly leukemia, and he and his team have translated their seminal findings into new, precise treatments that stop cancer while causing minimal side effects.
Dr. Gilliland earned a Ph.D. in microbiology from the University of California, Los Angeles, in 1980 and a medical degree from the University of California, San Francisco, in 1984. He has received many awards and honors in his career; including election to the National Academy of Sciences in 2015; the William Dameshek Prize from the American Society of Hematology; the Emil J. Freireich Award from the MD Anderson Cancer Center; and the Stanley J. Korsmeyer Award from the American Society for Clinical Investigation, of which he is an elected member. He is also an elected member of the Association of American Physicians.